{
    "ticker": "ZIMV",
    "name": "Zymeworks Inc.",
    "description": "Zymeworks Inc. is a biotechnology company focused on developing multifunctional therapeutics, primarily in the field of oncology. Founded in 2003 and headquartered in Vancouver, Canada, Zymeworks leverages its proprietary ZymeLink\u2122 and ZymeCAD\u2122 platforms to create a new class of therapeutic molecules called Zymeworks' Therapeutics. The company aims to address unmet medical needs by providing innovative and effective treatments for various cancers. Zymeworks is known for its commitment to advancing the science of protein engineering and has established partnerships with leading pharmaceutical companies to enhance the development and commercialization of its product candidates. The company\u2019s lead product candidate, ZW25, is a bispecific antibody designed to target and engage cancer cells with the goal of improving patient outcomes. Zymeworks also has a pipeline of other promising candidates, including ZW49, which is in clinical trials for the treatment of solid tumors. With a focus on collaboration and innovation, Zymeworks strives to push the boundaries of cancer treatment and provide hope to patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, British Columbia, Canada",
    "founded": "2003",
    "website": "https://www.zymeworks.com",
    "ceo": "Ali Tehrani",
    "social_media": {
        "twitter": "https://twitter.com/Zymeworks",
        "linkedin": "https://www.linkedin.com/company/zymeworks/"
    },
    "investor_relations": "https://investors.zymeworks.com",
    "key_executives": [
        {
            "name": "Ali Tehrani",
            "position": "CEO"
        },
        {
            "name": "Gordon Wong",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ZW25",
                "ZW49"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zymeworks Inc. | Innovative Biotherapeutics for Cancer Treatment",
        "meta_description": "Explore Zymeworks Inc., a leader in biotechnology focused on developing novel therapies for cancer. Learn about our innovative platforms and promising drug candidates.",
        "keywords": [
            "Zymeworks",
            "Biotechnology",
            "Cancer Treatment",
            "Therapeutics",
            "ZW25",
            "ZW49"
        ]
    },
    "faq": [
        {
            "question": "What does Zymeworks specialize in?",
            "answer": "Zymeworks specializes in developing multifunctional therapeutics for oncology."
        },
        {
            "question": "Who is the CEO of Zymeworks?",
            "answer": "Ali Tehrani is the CEO of Zymeworks Inc."
        },
        {
            "question": "Where is Zymeworks headquartered?",
            "answer": "Zymeworks is headquartered in Vancouver, British Columbia, Canada."
        },
        {
            "question": "What are Zymeworks' main products?",
            "answer": "Zymeworks' main product candidates include ZW25 and ZW49."
        },
        {
            "question": "When was Zymeworks founded?",
            "answer": "Zymeworks was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "REGN",
        "MRNA"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "CELG",
        "JNJ"
    ]
}